High-Throughput Screening in Drug Discovery

High-Throughput Screening (HTS) in drug discovery is a core technology in modern drug research and development. It utilizes automated equipment and large-scale experimental platforms to systematically test thousands of small molecule compounds, biomolecules, or natural products in a short time to screen for candidate drugs with potential biological activity. HTS integrates robotic technology, micro-dosing systems, multi-channel detection platforms, and data analysis algorithms, significantly enhancing drug discovery efficiency while ensuring experimental accuracy and reproducibility. It is primarily applied in the initial screening stage after target validation, rapidly identifying compounds that interact with disease-related targets through specific in vitro or cellular models. HTS serves as a bridge between basic research and clinical translation, with its efficiency and accuracy directly affecting the speed and cost of the entire drug development process. In various research fields such as cancer, autoimmune diseases, infectious diseases, and neurodegenerative diseases, HTS has become a means of finding new small molecule drugs, antibody drugs, or lead compounds. Despite its maturity in both theoretical and practical terms, HTS faces certain challenges such as insufficient physiological relevance of screening systems, high false positive rates, and varied quality of compound libraries. To improve screening efficiency, more research is exploring medium-throughput screening and high-content screening as multidimensional methods to supplement the shortcomings of traditional HTS.

 

The process of High-Throughput Screening in drug discovery usually includes multiple stages such as prescreening, primary screening, secondary screening, and validation. The primary screening stage is mainly used for quickly eliminating inactive compounds, retaining a small number of potentially active 'hit molecules'; the secondary screening stage further confirms their activity and excludes false positives; the final validation step involves structural optimization, dose-dependency analysis, and cross-validation with other targets to ensure specificity and safety of the candidate drug molecules. Additionally, with the introduction of artificial intelligence, machine learning, and big data platforms, HTS is moving towards 'intelligentization.' AI models can predict molecular activity based on existing screening results, assist in compound design, and optimize screening processes, thereby significantly improving hit rates and development efficiency.

 

The core advantages of High-Throughput Screening in drug discovery lie in its speed and breadth. By conducting parallel experiments on microplates (commonly 96-well, 384-well, or even 1536-well), researchers can complete tens of thousands to millions of bioactivity tests in days or even hours, greatly accelerating the new drug development process. Different types of HTS methods can be divided into target-based screening and phenotype-based screening according to differences in detection objects and mechanisms. The former is usually constructed for known functional proteins (such as receptors, enzymes, channels, etc.), suitable for drug development paths with clear mechanisms; the latter focuses on observing the overall response of cells, tissues, or model organisms, more suitable for drug screening in diseases with unknown mechanisms or multiple factors. Regardless of the strategy, HTS must ensure the sensitivity, specificity, and stability of the detection system.

 

Constructing an appropriate screening model is key to success in High-Throughput Screening in drug discovery. Common models include enzyme activity assays, receptor binding experiments, reporter gene systems, cytotoxicity assessments, and fluorescence imaging analysis, which can reflect the biological effects of potential drug molecules. HTS not only requires controllability of the experimental system but also poses high demands on data processing and statistical analysis. The Z' factor (Z value) is an important indicator for evaluating the quality of the screening system, typically requiring a Z' value greater than 0.5 to enter the formal screening stage.

 

Biotage provides high-quality detection and analysis services, offering strong guarantees to shorten research and development cycles and improve hit efficiency with high-standard processes, highly reproducible results, and professional technical support.

 

Biotage - Characterization of biopharmaceuticals, a premium provider of multi-group biomolecule mass spectrometry detection services

 

Related services: